Back to results
US 8,709,473 B1Granted
Method of targeting hydrophobic drugs to vascular lesions
AssigneeAbbott Cardiovascular Systems Inc.
InventorsDariush Davalian, John Stankus, Yuet Mei Khong, O. Mikael Trollsas, Syed F. A. Hossainy
Life of this patent
Estimating the term…
Abstract
This invention relates to the targeted delivery of hydrophobic drugs or combinations of hydrophobic drugs with photodynamic therapy agents to vascular lesions by complexation of the drugs to blood serum lipoproteins, which have an affinity for and accumulate in such vascular lesions.
Claims15
A method of targeting drug delivery to a vascular lesion, comprising:
- providing a core-shell carrier comprising a lipophilic shell layer that is unstable to a plasma protein;
- providing a non-photodynamic hydrophobic drug linked to a porphyrin and loaded into the core-shell carrier, the porphyrin comprising a deuteroporphyrin IX diester;
- and
- administering the linked drug/porphyrin-loaded core-shell carrier into the bloodstream of a patient in need thereof;
- wherein,
- when the core-shell carrier contacts a plasma protein in the patient's bloodstream, the core-shell carrier is disrupted, releasing the linked drug/porphyrin, which then forms a complex with a plasma protein that may be the same as or different than the plasma protein that caused the disruption of the core-shell carrier;
- wherein the linked drug/porphyrin comprises a biocompatible, biodegradable linker joining the drug to the porphyrin;
- and
- wherein the core-shell carrier is selected from the group consisting of a plasma protein unstable micelle, a plasma protein unstable liposome and a plasma protein unstable polymerosome.
6 more elements
Dependencies are inferred from the claim text.